Scaling Up and Out – Drastically Upsizing or Upscaling Your Cell and Gene Therapies

20 Jan 2023
11:00
Manufacturing Advanced Therapies Track
SPONSORED BY
MicrofluidX
WuXi Advanced Therapies

11:00am Chair Introduction

Sumit Verma, Senior Vice President, Global Strategic Manufacturing, Iovance Biotherapeutics

 

11:05am Presentation: TBC

Julie G. Allickson, Director, Mayo Clinic Center for Regenerative Medicine & Associate Professor of Regenerative Medicine, Mayo Clinic

 

11:20am Presentation: The Future is Scalable: Novel Technologies for Improving Access to Advanced Therapies

  • Adeno-associated viral (AAV) and Lentiviral (LV) vectors are important gene delivery tools for cell and gene therapies, but achieving scalable yields using plasmid-based manufacture remains an industry challenge and affects the accessibility of novel treatments
  • Disruptive technologies, removing or reducing the use of plasmids, have the potential to address these challenges
  • Plasmid-free TESSA™ technology has been shown to improve AAV production by over tenfold compared with plasmid-free approaches. LentiVEX™ stable cell lines will further enable efficient production of LV vectors compared with transient technologies

 David Chang, Chief Executive Officer, WuXi Advanced Therapies and OXGENE

 

11:35am Presentation: TBC

 Speaker TBC

 

11:50am Presentation: Eliminating Process Translation: How To Scale Up CGTs From R&D To Manufacturing Overnight!

  • Bioreactor technologies and strategies for scale-up/down for cell and gene therapies and case studies
  • Upstream process analytical technologies and strategies for scale-up/down for cell and gene therapies and case studies

James Kusena, Vice President – Bioprocessing and Applications , MicroFluidX

 

12:05pm Closing Panel with Q&A

With all session participants

Speakers

David Chang
Chief Executive Officer
WuXi Advanced Therapies
James Kusena
Vice President, Bioprocessing & Applications
MicrofluidX
Julie G. Allickson
Director, Mayo Clinic Center for Regenerative Medicine & Associate Professor of Regenerative Medicine
Mayo Clinic
Sumit Verma
Senior Vice President, Commercial Manufacturing
Iovance Biotherapeutics Inc